Plasmid DNA Contract Manufacturing Market (2026 - 2033)

Plasmid DNA Contract Manufacturing Market Summary

The global plasmid DNA contract manufacturing market size was valued at USD 500.0 million in 2025 and is projected to grow from USD 600.0 million in 2026 to USD 1,900.0 million in 2033, at a CAGR of 19.3% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 48.5% in 2025. The market is primarily driven by the growing pipeline of cell and gene therapies, increasing demand for viral vector production, rising outsourcing activities among biotechnology and pharmaceutical companies, and expanding investments in advanced biologics manufacturing. The increasing use of plasmid DNA as a critical starting material in gene therapies, CAR-T therapies, and vaccine development is further supporting market growth.

The growing adoption of outsourcing models among biotechnology and pharmaceutical companies is increasing demand for specialized plasmid DNA contract manufacturing services. Contract development and manufacturing organizations (CDMOs) offer expertise in process development, GMP production, analytical testing, and regulatory support, enabling therapy developers to accelerate product development while reducing capital investment requirements. The expansion of clinical pipelines for gene-modified therapies continues to create demand for high-quality plasmid DNA manufacturing capacity.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Industry participants are expanding manufacturing capabilities and forming strategic collaborations to address the increasing demand for plasmid DNA production services. For instance, in May 2025, Wacker Biotech and Expression Manufacturing entered into a strategic partnership to provide an integrated manufacturing solution for lentiviral-based gene and cell therapies by combining plasmid DNA and viral vector manufacturing capabilities. In addition, in June 2025, Probio expanded its Gene Therapy Center of Excellence in Hopewell to strengthen large-scale plasmid DNA and viral vector manufacturing capacity. Such developments are enhancing service availability and supporting the growth of the plasmid DNA contract manufacturing market.

Analyst Perspective

The plasmid DNA contract manufacturing market is witnessing strong growth, driven by the expanding pipeline of cell and gene therapies, increasing demand for viral vector production, and rising outsourcing activities among biotechnology and pharmaceutical companies. As plasmid DNA serves as a critical raw material for gene therapies, CAR-T therapies, and DNA-based vaccines, demand for high-quality GMP manufacturing services continues to increase. Contract manufacturers are investing in capacity expansion, process optimization, and integrated manufacturing capabilities to address growing customer requirements. In addition, increasing clinical trial activity and commercialization of advanced therapies are expected to create significant long-term growth opportunities for the market.

Application Insights

By application, the cell & gene therapy segment held the largest market share of around 60.5% in 2025 and is expected to continue to dominate the market during the forecast period. The segment's growth is driven by the expanding pipeline of cell and gene therapies and the increasing demand for outsourced plasmid DNA manufacturing services used in viral vector and gene-modified cell production. For instance, in August 2025, Bionova Scientific expanded its 10,000-square-foot plasmid DNA (pDNA) development and production facility in Texas to support CDMO services. The facility is designed to provide research-grade and clinical-to-commercial-scale Current Good Manufacturing Practice (CGMP) plasmid DNA production, strengthening the company's capabilities in supporting cell and gene therapy developers. Such capacity expansions are contributing to the segment's growth.

The immunotherapy segment of the plasmid DNA contract manufacturing market is expected to grow steadily during the forecast period. The segment's high growth is mainly due to increased research and development activities in immunotherapy. The increasing demand for oncology immunotherapy is another significant factor driving the segment’s growth. The rising number of cancer cases has led to the development of more oncology-based immunotherapy products, thereby supporting the segment’s growth in the plasmid DNA contract manufacturing market.

End User Insights

The pharmaceutical and biotechnology companies end user segment held the largest revenue share of around 59.0% in 2025, driven by the growing pipeline of plasmid DNA-based therapeutics worldwide. Moreover, an increasing number of pharma and biopharma companies outsourcing their plasmid DNA manufacturing to contract manufacturers is a primary driver of growth in the plasmid DNA contract manufacturing market.

The research institutes segment is expected to grow at the fastest CAGR during the forecast period, owing to increasing funding for cell & gene therapy-based research. Research institutes are focusing heavily on R&D in cell & gene therapies due to growing demand. Hence, increasing funding, coupled with the growing demand for plasmid DNA-based therapeutics, will strongly propel the segment’s growth in the plasmid DNA contract manufacturing market.

Therapeutic Area Insights

By therapeutic area, the cancer segment dominated the plasmid DNA contract manufacturing market, accounting for around 39.0% of revenue in 2025. The segment's high growth is mainly due to the expanding pipeline and the current portfolio of plasmid DNA-based therapeutics in oncology. Moreover, the increasing prevalence of cancer cases worldwide is another significant factor supporting research on plasmid DNA in oncology.

The infectious diseases segment is expected to grow at the fastest CAGR during the forecast period. Growth of the segment is driven by increasing development and commercialization of DNA vaccines, gene-based therapeutics, and other advanced therapies targeting infectious diseases. For instance, in April 2025, ProBio launched GMP plasmid DNA manufacturing services at its Hopewell facility to enable rapid production of clinical-grade plasmid DNA. The service is designed to accelerate manufacturing timelines and support developers of gene therapies, cell therapies, and vaccine candidates, including those targeting infectious diseases. Such service expansions are expected to strengthen manufacturing capabilities and support growth in the segment during the forecast period.

Regional Insights

North America dominated the plasmid DNA contract manufacturing market, accounting for approximately 48.5% of revenue in 2025, primarily driven by the strong presence of cell and gene therapy developers, rising outsourcing of plasmid DNA manufacturing, and the availability of well-established contract development and manufacturing organizations (CDMOs). The U.S. remains a key contributor due to its advanced biotechnology ecosystem, growing clinical pipeline of gene-based therapies, and continuous investments in GMP manufacturing infrastructure. Furthermore, increasing collaborations between therapy developers and contract manufacturers continue to support regional market growth.

To learn more about this report, Download Free Sample Report

Asia Pacific Plasmid DNA Contract Manufacturing Market Trends

The Asia Pacific marketis expected to grow at the fastest CAGR during the forecast period. The growth of this regional market is driven by increasing outsourcing activities, expanding biopharmaceutical manufacturing capabilities, and the availability of cost-competitive production services. Countries such as India and China are attracting global biotechnology and pharmaceutical companies seeking scalable and cost-efficient manufacturing solutions for advanced therapies. For instance, in November 2025, Bharat Biotech expanded its presence in the CRDMO sector through Nucelion Therapeutics, its dedicated cell and gene therapy business. The expansion includes GMP capabilities for plasmid DNA, viral vector, and non-viral vector manufacturing, strengthening India's position as a growing outsourcing destination for advanced biologics and gene therapy manufacturing services.

Key Plasmid DNA Contract Manufacturing Market Companies Insights

Companies operating in the plasmid DNA contract manufacturing market are adopting strategic initiatives such as partnerships, collaborations, capacity expansions, acquisitions, and service portfolio enhancements to strengthen their market presence and expand manufacturing capabilities.

Key Plasmid DNA Contract Manufacturing Market Companies

The following key companies have been profiled for this study on the plasmid DNA contract manufacturing market.

• Charles River Laboratories

• VGXI, Inc.

• PlasmidFactory GmbH & Co. KG

• Boehringer Ingelheim

• BioCina

• TriLink Biotechnologies

• Esco Aster Pte. Ltd.

• Thermo Fisher Scientific, Inc.

• VIVE biotech

• Lonza

Recent Developments

• In January 2026, Bionova Scientific formed a manufacturing alliance with Syenex to expand access to plasmid DNA manufacturing services for gene and cell therapy developers. The collaboration combines Bionova Scientific’s manufacturing capabilities with Syenex’s IS-free cell line technology to support the production of stable and reproducible plasmid vectors for advanced therapy applications.

• In August 2025, WACKER and Gearbox Biosciences entered into a strategic partnership focused on advancing plasmid DNA manufacturing technologies. The collaboration aims to support antibiotic-free manufacturing approaches and improve the production of complex plasmid DNA sequences used in advanced therapeutics. Such initiatives are expected to enhance manufacturing efficiency, scalability, and process flexibility for contract manufacturing applications.

Global Plasmid DNA Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends and opportunities across each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the plasmid DNA contract manufacturing market report based on application, therapeutic area, end user, and region:

To learn more about this report, Download Free Sample Report

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Cell & Gene Therapy

  • Immunotherapy

  • Others

• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

  • Cancer

  • Infectious Diseases

  • Autoimmune Diseases

  • Cardiovascular Diseases

  • Others

• End-user Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical and Biotechnology Companies

  • Research Institutes

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Rest of EU

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    •  South Korea

    • Rest of APAC

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of LATAM

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Rest of MEA